| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The viability of MCF7 cells is considerably reduced by TH1834 (0-500 μM; 1 hour) [1]. MCF7 cells treated with TH1834 (0-500 μM; 1 hour) exhibit a considerable increase in cytotoxicity [1]. MCF7 cells are exposed to 500 μM of TH1834 for one hour, which causes caspase 3 activation [1]. In vitro, TH1834 dramatically reduces Tip60 activity. In breast cancer, TH1834 treatment increases unrepaired DNA damage and induces death in cells [1].
|
|---|---|
| Cell Assay |
Cell Viability Assay [1]
Cell Types: MCF7 cells Tested Concentrations: 0μM, 0.5μM, 5μM, 50μM and 500μM Incubation Duration: 1 hour Experimental Results: The viability of MCF7 cells was Dramatically diminished. Cytotoxicity assay[1] Cell Types: MCF7 Cell Tested Concentrations: 0 μM, 0.5 μM, 5 μM, 50 μM and 500 μM Incubation Duration: 1 hour Experimental Results: Cytotoxicity increased Dramatically at all concentrations used. Western Blot Analysis[1] Cell Types: MCF7 Cells Tested Concentrations: 500 μM Incubation Duration: 1 hour Experimental Results: In an independent assay, significant caspase 3 activation was observed in MCF7 cells. |
| References |
| Molecular Formula |
C33H40N6O3
|
|---|---|
| Molecular Weight |
568.7091
|
| Exact Mass |
568.316
|
| CAS # |
2108830-08-4
|
| Related CAS # |
TH1834 dihydrochloride;2108830-09-5
|
| PubChem CID |
91826512
|
| Appearance |
White to light yellow solid powder
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
42
|
| Complexity |
761
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N(C([H])([H])C1C([H])=C([H])C(C2N=NN(C([H])([H])C(=O)O[H])N=2)=C([H])C=1[H])C([H])([H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
XERATECPNBWJFP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H40N6O3/c40-32(41)26-39-35-33(34-36-39)30-14-10-28(11-15-30)25-38(22-18-27-8-2-1-3-9-27)21-6-7-23-42-31-16-12-29(13-17-31)24-37-19-4-5-20-37/h1-3,8-17H,4-7,18-26H2,(H,40,41)
|
| Chemical Name |
2-[5-[4-[[2-phenylethyl-[4-[4-(pyrrolidin-1-ylmethyl)phenoxy]butyl]amino]methyl]phenyl]tetrazol-2-yl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~17.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7584 mL | 8.7918 mL | 17.5837 mL | |
| 5 mM | 0.3517 mL | 1.7584 mL | 3.5167 mL | |
| 10 mM | 0.1758 mL | 0.8792 mL | 1.7584 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
